Purple Biotech Ltd.PPBT
Price (close)
$1.48
Market cap
—
P/E
—
Revenue (FY)
—
Net income
-$26.4M
Dividend yield
—
1-year total return
-74.4%
Net margin
—
Revenue growth
—
Debt / equity
—
What Purple Biotech Ltd. does.
developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. We are focused
on advancing our lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging
both T cells and NK cells. Capping technology confines immune activation to the TME, significantly expanding the therapeutic window versus
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | — | — | — | — | — |
| Net income | $28.0M | $18.4M | -$21.7M | -$19.9M | -$7.2M | -$26.4M |
| Free cash flow | $1.5M | -$489,000 | -$16.8M | -$19.9M | — | -$5.7M |
More on PPBT.
- Purple Biotech Ltd. summary
- Purple Biotech Ltd. financial statements
- Purple Biotech Ltd. key metrics
- Purple Biotech Ltd. health scores and style box
- Purple Biotech Ltd. earnings
- Purple Biotech Ltd. dividends
- Purple Biotech Ltd. valuation
- Purple Biotech Ltd. ownership and insiders
- Purple Biotech Ltd. peers
Figures from Purple Biotech Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.